xudahai
Lv0
0 积分
2022-12-09 加入
-
Pembrolizumab Plus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes After 5 Years of Follow-Up
11天前
已完结
-
Antibody-drug conjugates in lung and breast cancer: Current evidence and future directions – a position statement from the ETOP IBCSG Partners Foundation
12天前
已完结
-
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
13天前
已完结
-
Opportunities and challenges following approval of resmetirom for MASH liver disease
13天前
已完结
-
Antiviral Therapy Utilization and 10-Year Outcomes in Resected Hepatitis B Virus– and Hepatitis C Virus–Related Hepatocellular Carcinoma
21天前
已完结
-
Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma
24天前
已完结
-
Telomere length and risk of cirrhosis, hepatocellular carcinoma, and cholangiocarcinoma in 63,272 individuals from the general population
29天前
已完结
-
Telomere length and risk of cirrhosis, hepatocellular carcinoma, and cholangiocarcinoma in 63,272 individuals from the general population
29天前
已关闭
-
Recurrent Intrahepatic Cholangiocarcinoma: A 10-Point Score to Predict Post-Recurrence Survival and Guide Treatment of Recurrence
1个月前
已完结
-
Risk factors, patterns, and outcome predictors of late recurrence in patients with hepatocellular carcinoma after curative resection: A large cohort study with long-term follow-up results
1个月前
已完结